Cromodyn

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cromodyn

What is Cromodyn?

Cromodyn is a pharmaceutical formulation containing the active substance sodium cromoglicate, a therapeutic agent classified as a mast cell stabilizer. It is primarily utilized in the management and prevention of various allergic conditions by addressing the underlying cellular mechanisms of the inflammatory response.

Mechanism of Action

The therapeutic effect of Cromodyn is derived from its ability to inhibit the degranulation of sensitized mast cells. Mast cells are specialized immune cells that play a central role in allergic reactions. When these cells encounter specific allergens, they typically release chemical mediators, such as histamine and leukotrienes, which trigger symptoms like swelling, itching, and mucus production.

Sodium cromoglicate works by stabilizing the outer membrane of these mast cells, preventing the release of these inflammatory substances. Because it acts by preventing the initiation of the allergic cascade rather than neutralizing mediators already present in the system, the medication is characterized as a prophylactic treatment.

Clinical Applications

Cromodyn is employed across several medical contexts to control chronic allergic inflammation. Its use is generally categorized based on the organ system affected:

  • Respiratory Health: It is used as an inhalation therapy for the long-term management of bronchial asthma. It helps reduce bronchial hyper-responsiveness and the frequency of asthma attacks triggered by exercise, cold air, or environmental pollutants.
  • Ocular Conditions: In ophthalmic solutions, it is applied to treat allergic conjunctivitis, helping to alleviate redness, itching, and discharge associated with seasonal or perennial allergies.
  • Nasal Symptoms: It is used to manage allergic rhinitis, providing relief from nasal congestion, sneezing, and runny nose.
  • Gastrointestinal Use: In certain oral forms, it may be used to manage systemic mastocytosis or food allergies by limiting the allergic response within the digestive tract.

General Characteristics

Unlike antihistamines, which are often used for the immediate relief of acute symptoms, Cromodyn is most effective when used consistently over time. It does not possess intrinsic bronchodilatory or anti-inflammatory properties similar to corticosteroids, nor is it effective for the reversal of an acute allergic emergency or an active asthma attack. Its primary value lies in its high safety profile and its role in the long-term stabilization of the immune response in patients prone to allergic sensitivities.

What side effects are possible with Cromodyn?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reaction profile of Sodium Cromoglycate (Cromodyn) based on frequency and affected body system. Many of the reported effects, particularly with inhaled or topical use, are localized and transient in nature.

Frequency-Classified Adverse Reactions

The profile shows that Common reactions often include headache, diarrhea, cough, and nausea, which are frequently reported across different formulations. Local irritation, such as transient stinging or burning at the site of administration, is also a commonly documented effect of the nasal or ophthalmic solutions. Rare adverse reactions are explicitly documented, primarily involving severe immune-mediated responses.

System-Organ Classes and Serious Reactions

Adverse effects are formally grouped into categories such as Gastrointestinal Disorders (e.g., abdominal pain, vomiting) and Respiratory Disorders (e.g., throat irritation, bronchospasm). The most serious adverse reactions listed in regulatory texts, though rare, include anaphylactic reactions, angioedema, laryngeal edema, and severe pulmonary infiltrates with eosinophilia. Use is primarily restricted to individuals without a known hypersensitivity to Sodium Cromoglycate.

Population-Specific Safety Notes

The safety profile includes specific considerations for certain patient groups. Safety and effectiveness are not established below the age of four years for the ophthalmic form or below two years for the oral and inhalation forms. Caution is advised for individuals with known decreased renal or hepatic function, as the compound is eliminated via both biliary and renal routes. Use during pregnancy is generally advised only if clearly necessary.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Cromodyn

Component Official Regulatory Statement
Documented overdose presentations No specific clinical syndrome or cluster of acute symptoms is documented in regulatory labeling due to the compound’s very low systemic toxicity.
Physiological systems affected (as stated in label) Acute overdosage is not documented to cause specific severe effects in major organ systems, reflecting the drug's property of poor systemic absorption from local administration sites.
Dose-related or exposure-related factors (if applicable) Acute toxicity occurs only at very high exposure levels in animal studies; systemic absorption in humans is minimal, suggesting low intrinsic overdose risk.
Population-specific overdose notes (if applicable) Regulatory documents note that dosage adjustment is required in patients with decreased renal or hepatic function for formulations with systemic absorption, indicating a need for monitoring in these populations during over-exposure.
Emergency-response statements (as written in official documents) Regulators mandate to seek professional assistance or contact a Poison Control Center immediately following accidental ingestion or over-administration.
When immediate medical help is required (label-derived phrasing only) Immediate medical assistance is required upon suspected or actual accidental ingestion of the product, even if the patient is without symptoms.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Characterized by an extremely low order of acute toxicity and a wide margin of safety, as defined by FDA and EMA documentation.
Regulatory basis (EMA / FDA / etc.) Information is derived from the FDA Prescribing Information and EMA/National Summary of Product Characteristics (SmPCs).
Overdose-context constraints (as defined in official documents) Management is limited to medical observation and supportive/symptomatic treatment, as no specific antidote is known.

Resulting Overdose Structure

Official Overdose Statements:

  • The official prescribing information states that due to the compound's low systemic toxicity and minimal absorption, acute overdosage is highly unlikely to cause serious systemic effects.
  • Regulatory documents explicitly require patients to contact a Poison Control Center immediately or seek professional assistance in the event of accidental ingestion or over-administration.
  • Specific government labeling indicates that, in many overdosage scenarios, medical observation is the only necessary intervention.
  • No specific antidote is known for the drug; therefore, management of potential symptoms is officially described as symptomatic and supportive.

Connection to the overall overdose profile (2–4 sentences): The regulatory overdose profile for Cromodyn is strictly defined by its low order of toxicity and minimal systemic absorption, which establish a wide margin of safety. Consequently, official guidance mandates immediate professional assessment, such as contacting a Poison Control Center, followed by symptomatic management and monitoring. The profile officially notes the lack of specific, severe systemic outcomes directly tied to acute overdosage.

Therapeutic Uses of Cromodyn

Cromodyn is commonly used as a preventative agent across multiple allergic and inflammatory domains. It is utilized for supporting symptomatic management in the following areas.

Therapeutic Focus and Symptom Domains

This medicine is primarily used to help manage conditions characterized by episodic or fluctuating manifestations, including mild to moderate bronchial asthma, seasonal and perennial allergic rhinitis, various forms of allergic conjunctivitis, and systemic mastocytosis-related digestive discomfort. In the respiratory domain, it provides preventative support against cough and breathing difficulties triggered by irritants.

It is relevant for easing challenging manifestations such as frequent sneezing, bothersome itching, and congestion in the nasal passages, which may create noticeable functional strain during periods of heightened exposure. For eye discomfort, it is commonly used for managing symptoms that may become intense, such as eye itching and redness.

Patient-Oriented Benefit

Its use supports general well-being and assists with maintaining functional stability when symptoms may become more noticeable.

Quick Fact Description
Primary Role Symptomatic management in inflammatory and allergic domains
Benefit Focus Supports functional stability during episodes of heightened discomfort

Regulatory References

  1. NIH National Library of Medicine overview

Eligibility and Restrictions for Use

Cromodyn (Sodium Cromoglycate) eligibility is defined by strict regulatory criteria documented in official prescribing information. Use is contraindicated in patients with a known hypersensitivity to the active ingredient or any of the formulation’s excipients. This constitutes the primary absolute exclusion.

Eligibility is generally established for adults and children aged two years and older. However, use in children under two years is highly conditional and must be reserved for severe disease where the potential benefits are documented to outweigh the risks, as safety and efficacy are not fully established in this age group.

Regulatory guidance imposes specific limitations for patients with decreased renal or hepatic function, requiring that the recommended dosage be formally reduced. Caution is also advised for older adults, reflecting the greater frequency of potential decline in organ function within this population.

For reproductive health, the medicine is classified as Pregnancy Category B. Official documents state it should be used during pregnancy only if clearly needed. Similarly, caution is warranted during breastfeeding because it is unknown whether the drug is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Cromodyn Sodium is notably limited due to its minimal systemic absorption across all routes of administration. Regulatory information indicates a general absence of significant systemic drug-drug interactions involving common metabolic enzymes (e.g., CYP) or drug transporters, meaning no common systemic medications are listed as contraindicated due to these mechanisms.


Documented Interaction Constraints

Constraint Type Official Regulatory Statement
Systemic Drug Interactions No clinically significant systemic drug-drug interactions are known or listed in official labeling.
Physical & Food Restrictions The oral solution must not be mixed with fruit juice, milk, or food, as this can physically interfere with the drug’s effectiveness. The oral dose must be taken separately from meals.
Ophthalmic Interactions The localized absorption of the ophthalmic solution may be decreased if co-administered with Oxymetazoline.

Population-Specific Considerations

The small portion of Cromodyn that is absorbed is eliminated through the kidneys (renal route) and liver (biliary route). Therefore, patients with known impaired hepatic function or impaired renal function require close monitoring. Official labeling advises that a dosage decrease should be considered in these patient populations to prevent potential accumulation and increased systemic exposure.

Mechanism of Action

The action of Sodium Cromoglycate (Cromodyn) is defined by its highly targeted, prophylactic mechanism, which intervenes at the cellular level to modulate the initiation of the inflammatory response.

Cellular Membrane Stabilization

This mechanism covers the drug’s primary interaction with mast cells. The drug stabilizes the mast cell plasma membrane by modulating the conductance of chloride channels and inhibiting the critical calcium ion (Ca^2+) influx necessary for cell activation. This mechanical arrest of the molecular activation sequence contributes to mast cell functional stability upon exposure to an external trigger.

Arresting the Inflammatory Mediator Cascade

The consequence of stabilization is the prevention of degranulation—the process by which mast cells empty their contents. This mechanism suppresses the sudden, massive local release of potent mediators, including histamine and leukotrienes. By arresting the molecular cascade, the drug results in diminished mediator-driven signaling pathways that otherwise induce localized increases in vascular permeability and afferent nerve discharges.

Prophylactic Mechanism and Functional Scope

The entire mechanism is centered on preemptive physiological modulation. The mechanism acts upstream of pathways designed for the rapid reversal of established effects. The necessity of blocking the cellular cascade at its earliest stage means the drug must be present in the tissue consistently and continuously to sustain the required threshold for cellular stability. This defines its functional scope as an agent that modulates the initial events of the IgE-mediated signaling pathway.

Dosage and Administration Information

Administration Guidelines for Cromolyn

Cromolyn (Cromolyn Sodium) is available in multiple forms, and the administration protocol is defined for each route. The medication must be administered on a fixed, regular schedule to achieve and maintain its intended effect.

Route of Administration Standard Dosing Frequency Special Preparation / Timing Rule
Oral Solution Four times daily (QID) Mix with water only; drink 30 minutes before meals and at bedtime.
Inhalation Solution Four times daily (QID) Administered via a power-driven nebulizer; requires regular intervals.
Nasal Solution Three to six times daily One spray per nostril; for prevention, may be started up to one week before exposure.
Ophthalmic Solution Four to six times daily 1 to 2 drops per eye; must be applied at regular intervals.

Age-Specific Administration:

  • Oral Solution: Adults and children 13 years and older start with 200 mg per dose; children 2–12 years start with 100 mg per dose. Dose adjustments may be necessary in patients with reduced hepatic function. Use in infants under 2 years of age is reserved for severe disease, with a dose not to exceed 20 mg/kg/day for infants up to six months of age.
  • Inhalation/Nasal/Ophthalmic: Specific age cut-offs (e.g., 2 years and older for inhalation, 6 years and older for nasal) apply as defined for the specific formulation.

Missed Dose and Procedural Notes:

If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule continued. Do not take a double dose to compensate for a missed one. The therapeutic effect relies entirely on continuous, regular dosing, which must be maintained as directed.

Recent Clinical Evidence

Cromodyn: Recent Clinical Evidence


Evidence for Prophylaxis in Allergic Rhinitis (Nasal Use)

Research has studied Cromodyn for seasonal and perennial allergic rhinitis, conditions marked by fluctuating symptoms. Studies are typically short-term, controlled Randomized Controlled Trials (RCTs). Researchers monitored patient-reported outcomes describing perceived discomfort and functional measures like the Total Nasal Symptom Score. Findings describe patterns observed in the adult and adolescent populations studied. The evidence base is broadly categorized as moderate, but follow-up durations were limited, meaning long-term effects are not fully established. Comparative evidence is lacking or inconsistent regarding the patterns observed when compared to other treatments.

Evidence for Managing Allergic Conjunctivitis (Ophthalmic Use)

Research has explored the use of ophthalmic Cromodyn in allergic conjunctivitis using Double-blind, Placebo-controlled RCTs and systematic reviews. Studies monitored outcomes related to physical discomfort, such as eye itching and redness. The evidence base is generally described as moderate, although reviews note many trials have small sample sizes and a high degree of variability in patterns observed across studies.

Evidence for Prophylaxis in Mild to Moderate Asthma (Inhaled Use)

Cromodyn was evaluated for mild to moderate bronchial asthma. Research examined functional outcomes, such as measures of lung function ( FEV1), and patient-reported outcomes. The evidence is limited for this indication. Systematic reviews found that data for certain groups, such as children, remain insufficient to confidently draw conclusions about patterns observed when compared to a placebo. The evidence is broadly categorized as Low/Insufficient.

Evidence Gaps and Areas of Uncertainty

Several key limitations exist in the broader evidence landscape for Cromodyn: Sample sizes were modest in many trials, evidence quality varies across studies, and data for long-term outcomes are insufficient. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Cromodyn (FAQ)

Q: How quickly should I expect Cromodyn to start working?

A: Regulatory product information describes varying onset times based on the specific dosage form. For nasal use, patients may begin to see clinical improvement within several days of consistent use. For the oral solution, improvement has been noted to occur between two to six weeks after starting treatment, with peak effects often reported in clinical studies after one to two weeks of consistent use.


Q: Are there any common mild side effects people report with Cromodyn?

A: Official regulatory documents indicate that common reactions often include systemic effects like headache, nausea, diarrhea, and cough. Localized irritation, such as transient stinging or burning at the site of administration, is also frequently documented with the nasal and ophthalmic solutions.


Q: Can children or teenagers take Cromodyn?

A: Cromodyn is generally established for use in adults and children aged two years and older for many formulations, though specific age limits may vary by dosage form. Use in children younger than two years is restricted to use in severe disease only, as safety and effectiveness are not fully established in this age group.


Q: Is Cromodyn safe for elderly patients?

A: Official guidance advises caution for older adults due to the greater frequency of potential decline in organ function. Official guidance notes that dose adjustments may be appropriate for individuals with reduced renal or hepatic function, which occurs more frequently in the older adult population.


Q: Does Cromodyn affect birth control pills?

A: Official regulatory information indicates no clinically significant systemic drug-drug interactions are known or listed, which generally applies to hormonal contraceptives. This is generally attributed to Cromodyn's minimal systemic absorption.


Q: Are pregnant or breastfeeding women allowed to take Cromodyn?

A: Cromodyn is classified as Pregnancy Category B. Official labeling states that use during pregnancy is recommended only if the potential benefit clearly outweighs the potential risk. Caution is also warranted during breastfeeding because it is unknown if the drug is excreted into human milk.


Q: What is the success rate of Cromodyn in clinical studies?

A: Clinical studies monitor patient outcomes and functional measures, with the overall evidence base for efficacy generally categorized as moderate to low, depending on the specific use. Regulatory summaries do not provide a single, universal 'success rate' percentage for the drug.


Q: Are there any tests needed before starting treatment with Cromodyn?

A: Patients with known impaired hepatic (liver) or renal (kidney) function are noted to require close monitoring, as the drug is eliminated via both routes. For these populations, regulatory documents suggest a dosage decrease may be appropriate.


Q: Is Cromodyn a type of antibiotic, painkiller, or something else?

A: Cromodyn is classified as a mast cell stabilizer, which belongs to a specific type of antiallergic agent. Its action is focused on modulating cellular events involved in allergic responses. It is not an antibiotic or a painkiller.


Q: How long does Cromodyn stay in your system?

A: The time it takes for half of the absorbed drug to be eliminated from the bloodstream is relatively short, approximately 80 to 90 minutes. For the oral solution, most of the dose is not absorbed into the body and is eliminated unchanged through the feces.


Q: Is Cromodyn known to cause drowsiness or affect driving?

A: Drowsiness is not listed as a common or frequent side effect in official regulatory documents. However, because drowsiness has been reported in some clinical trials, patients are generally advised to be aware of their personal reaction to the medication before engaging in activities that require full mental alertness, such as driving.


Q: Are there different brand names for the medicine Cromodyn?

A: Yes, the active ingredient, Cromolyn Sodium, is marketed under various brand names depending on the formulation and the region. The generic drug is available in multiple forms.


Q: Is there a generic version of Cromodyn available?

A: Yes, Cromolyn Sodium is available as a generic drug in various forms, including the oral concentrate solution and inhalation solution. This allows the active ingredient to be purchased under its non-proprietary name.


Q: Are there any documented cases of addiction or dependence with Cromodyn?

A: According to official regulatory classifications, Cromodyn is not scheduled as a controlled substance. It is not known to carry a risk of physical dependence.


Q: Can Cromodyn affect my mood or mental state?

A: Irritability has been included in some official post-marketing reports. Though major impact on mood or mental status is not a frequent observation in regulatory summaries, patients should monitor any mental state changes.


Q: Does Cromodyn interact with herbal supplements or vitamins?

A: Official labeling states no known clinically significant systemic drug-drug interactions. However, it is customary to disclose all products being taken, including herbal supplements and vitamins, to a healthcare provider when starting any new medication.


Q: What are the typical benefits people experience when taking Cromodyn?

A: Official information states that Cromodyn is used to help prevent and relieve symptoms associated with various allergic conditions, such as sneezing, runny nose, and allergic eye disorders. Official product information notes that for the oral solution, use is associated with improvement in symptoms of mastocytosis such as abdominal pain and diarrhea.


Q: Does Cromodyn affect my ability to operate heavy machinery?

A: As drowsiness has been reported in clinical trials, although not commonly, individuals should determine their personal reaction to the medication before engaging in activities that require full attention, such as operating heavy machinery or driving.

How should Cromodyn be stored and disposed of?

How to Store and Dispose of Cromodyn?

The official storage and disposal guidelines for Cromodyn (Sodium Cromoglycate) are established by regulatory bodies to maintain the product's integrity and safety. All requirements are mandatory and based on label information.

Official Storage and Handling

Requirement Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Protect from freezing, light, and excessive moisture.
Container Keep in the original container, tightly closed, with the cap in place.
Safety Keep out of the sight and reach of children.

Stability and Disposal

Sterile solution forms have a defined in-use stability period; the remaining contents must be discarded within 28 days or one month after opening. Regulatory documents mandate that unused or expired medicine must not be thrown away via wastewater or household waste. Consult a pharmacist for instructions on proper disposal according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cromodyn found in:

A-Z Index: